Krystal looks to Phase III as stock soars on data for gene therapy

With its lead gene therapy showing efficacy in healing wounds in a rare skin condition, Krystal has seen its market cap multiply sixfold since its 2017 IPO as it now looks ahead to starting Phase III testing in a matter of months.

Krystal Biotech Inc. (NASDAQ:KRYS) jumped $12.05 (41%) to $41.20 Monday after reporting that KB103 led to complete closure of five wounds by day 90 in three evaluable recessive dystrophic epidermolysis bullosa patients in the Phase II portion of the Phase I/II GEM trial. The primary endpoint in GEM's Phase II portion evaluates wound closure over 24 weeks as change in wound size, time to closure and duration of wound closure. ...